Nucleome Therapeutics raises oversubscribed £37.5 million Series A

Nucleome Therapeutics Limited, a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.

Nucleome’s breakthrough platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery.

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics.  “

Click here to find out more.

Recent news

Times Higher Education article – female academic founders

Times Higher Education article – female academic founders

Advanced Oxford member and collaborator considers the role of investors in supporting female academic founders Simonetta Manfredi is a professor of equality and diversity management, and the Director for Research, Innovation and Enterprise at Oxford Brookes...

read more
Amano Enzyme establishes new European hub at Milton Park

Amano Enzyme establishes new European hub at Milton Park

The world’s leading manufacturer of speciality enzymes, has established its new Europe, Middle East and Africa (EMEA) hub at Milton Park. Amano Enzymes, the Japanese biotechnology company - which uses its enzymes to boost the flavour, texture, colour, digestion and...

read more
Next step in expansion of The Oxford Science Park

Next step in expansion of The Oxford Science Park

Detailed planning application submitted for Plot 27 New R&D building part of >500,000 sq ft expansion plan as the Park innovation ecosystem grows. The Oxford Science Park (TOSP), one of Europe’s leading locations for science and technology companies, is...

read more
Loading...